![]() |
|
|
MJ Rogers, X Xiong, RJ Brown, DJ Watts, RG Russell, AV Bayless and FH Ebetino
Krebs Institute, Department of Molecular Biology and Biotechnology, University of Sheffield, UK.
The mechanisms by which bisphosphonate drugs inhibit osteoclast- mediated bone resorption are unclear. Effects of bisphosphonates on cellular enzymes, metabolic pathways, and osteoclast morphology have previously been described and could culminate in a generalized cytotoxic effect or a decreased capacity of osteoclasts to resorb bone. Recent studies of the structure-activity relationship for the bisphosphonate side chain indicate, however, that at least the newer generations of nitrogen-containing bisphosphonates probably act by binding to a specific target at a site that is complementary in structure to the bisphosphonate side chain. We have previously proposed that such a target for bisphosphonates is also present in amoebae of the cellular slime mold Dictyostelium discoideum, because growth of this microorganism is inhibited by a wide range of bisphosphonates in a manner that closely reflects the antiresorptive potencies of the bisphosphonates in vivo. We have added support for this view by examining the potency towards Dictyostelium of bisphosphonates in which slight changes in the structure of the side chain or conformational restrictions to the side chain have marked effects on antiresorptive potency. The changes in the side chain that affected the in vivo antiresorptive potency of the bisphosphonates consistently affected in a similar manner the potency of the bisphosphonates as inhibitors of the growth of Dictyostelium amoebae. These observations confirm that bisphosphonate drugs have a molecular target that is common to both Dictyostelium amoebae and osteoclasts.
This article has been cited by other articles:
![]() |
R. G. G. Russell Bisphosphonates: Mode of Action and Pharmacology Pediatrics, March 1, 2007; 119(Supplement_2): S150 - S162. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ortiz-Gomez, C. Jimenez, A. M. Estevez, J. Carrero-Lerida, L. M. Ruiz-Perez, and D. Gonzalez-Pacanowska Farnesyl Diphosphate Synthase Is a Cytosolic Enzyme in Leishmania major Promastigotes and Its Overexpression Confers Resistance to Risedronate. Eukaryot. Cell, July 1, 2006; 5(7): 1057 - 1064. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Dunford, K. Thompson, F. P. Coxon, S. P. Luckman, F. M. Hahn, C. D. Poulter, F. H. Ebetino, and M. J. Rogers Structure-Activity Relationships for Inhibition of Farnesyl Diphosphate Synthase in Vitro and Inhibition of Bone Resorption in Vivo by Nitrogen-Containing Bisphosphonates J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 235 - 242. [Abstract] [Full Text] |
||||
![]() |
G. Mundy, R. Garrett, S. Harris, J. Chan, D. Chen, G. Rossini, B. Boyce, M. Zhao, and G. Gutierrez Stimulation of Bone Formation in Vitro and in Rodents by Statins Science, December 3, 1999; 286(5446): 1946 - 1949. [Abstract] [Full Text] |
||||
![]() |
H. L. Benford, J. C. Frith, S. Auriola, J. Mönkkönen, and M. J. Rogers Farnesol and Geranylgeraniol Prevent Activation of Caspases by Aminobisphosphonates: Biochemical Evidence for Two Distinct Pharmacological Classes of Bisphosphonate Drugs Mol. Pharmacol., July 1, 1999; 56(1): 131 - 140. [Abstract] [Full Text] |
||||
![]() |
J. E. Fisher, M. J. Rogers, J. M. Halasy, S. P. Luckman, D. E. Hughes, P. J. Masarachia, G. Wesolowski, R. G. G. Russell, G. A. Rodan, and A. A. Reszka Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro PNAS, January 5, 1999; 96(1): 133 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Fleisch Bisphosphonates: Mechanisms of Action Endocr. Rev., February 1, 1998; 19(1): 80 - 100. [Abstract] [Full Text] |
||||